Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Fallopian Tube Endometrioid Adenocarcinoma × anetumab ravtansine × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Mesothelioma 2 Pancreatic Neoplasms 1 Lung Neoplasms 1 Fallopian Tube Endometrioid Adenocarcinoma 1 Adenocarcinoma of Lung 1

Interventions

anetumab ravtansine 1 Taxes 1 Paclitaxel 1 Immunoglobulin G 1 Disulfides 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03587311 2025-10-08

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting

Fallopian Tube Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡